RVC study reveals benefits of feline epicardial pacemakers
Cats are less likely to be considered for EP implantation.
Research from the Royal Veterinary College (RVC) has found that epicardial pacemakers (EPs) can result in positive outcomes for cats suffering from severe heart conditions.
Findings revealed that EP implantation supported artificial cardiac pacing (ACP), which was effective in resolving symptoms such as abnormally slow heart rates (bradyarrhythmia).
Cats are less likely to be considered for EP implantation, as they are better at tolerating bradyarrhythmia. It is usually reserved for cats displaying symptoms such as loss of consciousness, lethargy or a congestive heart.
There was also a lack of research into performing the procedure and the outcomes on quality of life.
A research team, led by Matteo Rossanese, investigated the outcomes of implantations for 39 cats across four animal hospitals. Using a two-part survey, the team sought to identify the clinical signs and health-related quality of life by measuring cat activity and owner satisfaction.
The findings confirmed that EP was a beneficial surgery for cats, contributing to a longer, better quality of life for cats.
The primary reasons that cats were referred for treatment included bradycardia and collapsing episodes. A third-degree atrioventricular block was found to be the most common indicator of pacemaker placement.
Owners reported a good improvement in their cat’s condition, rating their satisfaction at 9.9 out of 10.
The research team says that their findings also highlight the importance of a joined up approach between cardiology and cardiothoracic specialists in these cases.
Dr Rossanese, senior lecturer in small animal soft tissue surgery, said: “I am incredibly proud of the work our team has done to explore the use of epicardial pacemakers in cats.
“This study not only highlights the potential for significant improvements in quality of life for feline patients but also provides valuable evidence to guide clinicians in making confident decisions about this life-changing procedure.
“It has been a privilege to lead this study alongside a dedicated team of colleagues, and I hope these findings will encourage further advancements in veterinary cardiology.”
The full study can be found in the Journal of the American Veterinary Medical Association.
Image © RVC
The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.
